Solid Biosciences (SLDB) Common Equity: 2017-2024
Historic Common Equity for Solid Biosciences (SLDB) over the last 7 years, with Sep 2024 value amounting to $167.0 million.
- Solid Biosciences' Common Equity rose 15.70% to $167.0 million in Q3 2024 from the same period last year, while for Sep 2024 it was $167.0 million, marking a year-over-year increase of 15.70%. This contributed to the annual value of $126.5 million for FY2023, which is 40.25% down from last year.
- As of Q3 2024, Solid Biosciences' Common Equity stood at $167.0 million, which was down 13.57% from $193.2 million recorded in Q2 2024.
- In the past 5 years, Solid Biosciences' Common Equity ranged from a high of $253.0 million in Q1 2021 and a low of $22.2 million during Q3 2020.
- For the 3-year period, Solid Biosciences' Common Equity averaged around $172.0 million, with its median value being $167.0 million (2024).
- In the last 5 years, Solid Biosciences' Common Equity slumped by 79.52% in 2020 and then soared by 904.74% in 2021.
- Over the past 5 years, Solid Biosciences' Common Equity (Quarterly) stood at $132.1 million in 2020, then skyrocketed by 57.63% to $208.2 million in 2021, then grew by 1.66% to $211.7 million in 2022, then slumped by 40.25% to $126.5 million in 2023, then increased by 15.70% to $167.0 million in 2024.
- Its last three reported values are $167.0 million in Q3 2024, $193.2 million for Q2 2024, and $210.7 million during Q1 2024.